Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 12, 2025 06:00 ET | Source: Bio Green Med Solution, Inc.

Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

Bio Green Med Solution, Inc. (formerly Cyclacel Pharmaceuticals, Inc.) Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.
August 04, 2025 18:50 ET | Source: Cyclacel Pharmaceuticals, Inc.

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

- Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc....
April 02, 2025 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing...
March 24, 2025 07:30 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock

KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer...
December 05, 2024 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

BERKELEY HEIGHTS, N.J., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
June 26, 2024 09:15 ET | Source: Cyclacel

Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions

NOTICE OF INTENTION TO GRANT OF NEW EUROPEAN PATENT COVERING PLOGOSERTIB PHARMACEUTICAL COMPOSITIONS - Lengthens Patent Exclusivity to August 2040
January 30, 2024 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
January 02, 2024 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024

BERKELEY HEIGHTS, N.J., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
November 13, 2023 16:05 ET | Source: Cyclacel

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to...
November 07, 2023 09:15 ET | Source: Cyclacel

Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results

BERKELEY HEIGHTS, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...